Navigation Links
The IMF says journal editorial documents dramatic increase in survival since the 1980s
Date:9/11/2008

North Hollywood, CA September 11, 2008 - The International Myeloma Foundation (IMF)supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicianstoday said survival outcomes have improved dramatically for patients with multiple myeloma, cancer in the bone marrow that affects blood cell production. Writing in the October 10th edition of the Journal of Clinical Oncology*, IMF chairman Brian G.M. Durie, M.D., notes that 25 years ago only 48 percent to 66 percent of myeloma patients survived two years, depending on which treatment was used. By contrast today, two-year survival rates are around 90 percent.

"What has changed is not the research capability, it is the availability of potent new classes of drugs without the side effects typically associated with chemotherapy," says Dr. Durie. "The successful agents in myeloma are multifunctional with a diverse impact on cell function and pathways. This may well be the secret of success."

The editorial explains that drug design was spurred by the discovery that thalidomide, originally developed as a sedative, was effective against myeloma through multiple mechanisms of action. As a result we have potent, targeted drugs such as Revlimid® and Velcade®, with improved outcomes.

"The benefits and comparisons are particularly interesting looking at the results with lenalidomide (Revlimid) plus low-dose dexamethasone (steroid) compared with prior results with interferon and levamisole. There is essentially a doubling of survival at two years, with preliminary evidence that this survival will be maintained for at least three to four years."

Dr. Durie notes these achievements with myeloma are now benefiting a wide range of blood cancers as these drugs are being tested in non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other blood cancers. In the editorial he says the next step is to identify new agents with "greater efficacy or lesser toxicities" in this setting of already high response rates.


'/>"/>

Contact: Stephen Gendel
sgendel@biocompartners.com
212-918-4650
Weber Shandwick Worldwide
Source:Eurekalert

Related biology news :

1. News tips from the Journal of Neuroscience
2. Tips from the Journals of the American Society for Microbiology
3. Story ideas from the Journal of Lipid Research
4. Highlights from the September 2007 Journal of the American Dietetic Association
5. AGU journal highlights -- Sept. 6, 2007
6. Springer will publish Journal of Coastal Conservation
7. ESA celebrates 100 years of insect science journals
8. Springer and the New York Botanical Garden Press join forces to publish botanical journals
9. 200 journals join in theme issues on poverty and human development
10. New ETH Zurich article published in scientific journal Nature
11. Media highlights in the November issues of Biophysical Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
(Date:3/14/2016)... , March 14, 2016 NXTD ) ... mobile commerce market, announces the airing of a new series ... the week of March 21 st .  The commercials will ... its popular Squawk on the Street show. --> ... the growing mobile commerce market, announces the airing of a ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group ... Ross is the founder of GSCG affiliate Kimera Labs in Miami. , In 2004, ... hematopoietic stem cell transplantation for hematologic disorders and the suppression of graft vs. host ...
(Date:4/26/2016)... ... April 27, 2016 , ... ... Roca Rothgerber Christie LLP as an associate in the firm’s Intellectual Property practice ... electrical, mechanical and electromechanical patent applications. He has an electrical engineering and computer ...
(Date:4/26/2016)... , ... April 26, 2016 , ... Mr. Palmer created ... RPO, signing the first multi-million dollar, multi-year managed services contract in the U.S. intelligence ... Michael join our leadership team,” said John Younger, founder of Accolo. “We are ...
(Date:4/26/2016)... VIENNA and ... The prize recognizes the innovation capabilities ... innovations that will benefit patients and laboratory diagnostics ... ) , Norma Instruments , ... setting products in the field of hematology, announced ...
Breaking Biology Technology: